Chardan lowered the firm’s price target on Omega Therapeutics (OMGA) to $7 from $12 and keeps a Buy rating on the shares following the company’s Q4 and full year 2023 financial results, and corporate update. The company ended the year with cash, equivalents, and marketable securities of $73.4M compared to $125M at the end of 2022. The company has implemented a strategic prioritization and 35% headcount reduction in order to reduce its operating expense, the firm notes. Management now projects that its cash, which includes a $5.1M upfront payment from Novo Nordisk (NVO), is sufficient to fund operations into Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>